Item 7.01 Regulation FD Disclosure.



On January 4, 2021, Sio Gene Therapies Inc. (the "Registrant") issued a press
release announcing that it has agreed to sell its equity stake in Arvelle
Therapeutics ("Arvelle") to Angelini Pharma, as part of that company's cash
acquisition of 100% of the outstanding equity of Arvelle for up to $960 million
(the "Transaction").

A copy of this press release is furnished as Exhibit 99.1 to this report and is
incorporated herein by reference. The disclosures set forth in this Item 7.01
and Exhibit 99.1 to this report are furnished and shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or subject to the liabilities of that section. The information contained in this
Item 7.01 and Exhibit 99.1 to this report shall not be deemed incorporated by
reference into any other filing with the SEC made by us, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing.


Item 8.01  Other Events.

On January 4, 2021, the Registrant agreed to sell its equity stake in Arvelle to
Angelini Pharma, as part of the Transaction. The Transaction is expected to
close during the first calendar quarter of 2021, subject to the satisfaction of
customary closing conditions.

The Registrant expects to receive an upfront cash payment of $11.8 million with
up to an additional $8.2 million in potential regulatory and sales milestone
payments, totaling up to approximately $20.0 million in the Transaction. These
proceeds represent a substantial gain on the Registrant's initial investment in
Arvelle but are not expected to result in any income tax liabilities. This
infusion along with the Registrant's cash on hand at December 31, 2020 are
expected to support the development of the Registrant's three clinical-stage
development programs into calendar year 2022.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.
                                                            EXHIBIT INDEX
   Exhibit No.                                         Description of Document

      99.1                Press Release of     Sio Gene Therapies Inc.    ,

dated     January 4, 2021    .

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses